Mimedx Group Inc (NASDAQ:MDXG) Institutional Investor Positioning

April 16, 2018 - By Clifton Ray

MiMedx Group, Inc. (NASDAQ:MDXG) Logo

Sentiment for Mimedx Group Inc (NASDAQ:MDXG)

Mimedx Group Inc (NASDAQ:MDXG) institutional sentiment decreased to 1.01 in 2017 Q4. Its down -0.96, from 1.97 in 2017Q3. The ratio fall, as 102 investment managers increased and opened new equity positions, while 101 sold and decreased their stock positions in Mimedx Group Inc. The investment managers in our partner’s database now possess: 86.17 million shares, up from 77.22 million shares in 2017Q3. Also, the number of investment managers holding Mimedx Group Inc in their top 10 equity positions decreased from 2 to 1 for a decrease of 1. Sold All: 40 Reduced: 61 Increased: 63 New Position: 39.

MiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. The company has market cap of $797.23 million. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. It has a 23.09 P/E ratio. The companyÂ’s proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization.

The stock increased 3.01% or $0.21 during the last trading session, reaching $7.18. About 870,511 shares traded. MiMedx Group, Inc. (NASDAQ:MDXG) has declined 27.63% since April 16, 2017 and is downtrending. It has underperformed by 39.18% the S&P500.

Consonance Capital Management Lp holds 6.82% of its portfolio in MiMedx Group, Inc. for 5.99 million shares. Kestrel Investment Management Corp owns 657,000 shares or 2.89% of their US portfolio. Moreover, Senzar Asset Management Llc has 2.34% invested in the company for 726,300 shares. The Pennsylvania-based Millrace Asset Group Inc. has invested 1.76% in the stock. Tiedemann Wealth Management Llc, a New York-based fund reported 1.45 million shares.#img1#

MiMedx Group, Inc. (NASDAQ:MDXG) Ratings Coverage

Ratings analysis reveals 50% of MiMedx Group’s analysts are positive. Out of 4 Wall Street analysts rating MiMedx Group, 2 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $18.0 while the high is $21.0. The stock’s average target of $19 is 164.62% above today’s ($7.18) share price. MDXG was included in 11 notes of analysts from October 30, 2017. The stock has “Buy” rating by Needham on Monday, October 30. The firm has “Hold” rating by Needham given on Tuesday, February 20. The rating was downgraded by Lake Street to “Hold” on Monday, February 26. On Thursday, January 18 the stock rating was maintained by Needham with “Buy”. The stock of MiMedx Group, Inc. (NASDAQ:MDXG) has “Buy” rating given on Friday, December 1 by Needham. Piper Jaffray maintained the stock with “Buy” rating in Wednesday, December 13 report. On Tuesday, November 14 the stock rating was maintained by Needham with “Buy”. The rating was maintained by Needham on Wednesday, December 13 with “Buy”. Needham maintained the stock with “Buy” rating in Monday, January 8 report.

MiMedx Group, Inc. (NASDAQ:MDXG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: